Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-04-03
2007-04-03
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255050, C514S441000
Reexamination Certificate
active
10262237
ABSTRACT:
Novel methods for inhibiting angiogenesis and treating diseases associated with angiogenesis are described. The methods may comprise administering to a patient an effective amount of a 1,2-dithiol-3-thione derivative or metabolite thereof. Preferred compounds for use in the methods include 5-(2-pyrazinyl)-4methyl-1,2-dithiol-3-thione (Oltipraz) and its metabolites.
REFERENCES:
patent: 4138487 (1979-02-01), Barreau et al.
patent: 5571523 (1996-11-01), Lee et al.
patent: 5668117 (1997-09-01), Shapiro
patent: 5686436 (1997-11-01), Van Dyke
patent: 5691338 (1997-11-01), Prochaska et al.
patent: 5786344 (1998-07-01), Ratain et al.
patent: 6812248 (2004-11-01), Zhang et al.
patent: WO 96/24694 (1996-08-01), None
patent: WO 96/28114 (1996-09-01), None
patent: WO 97/03055 (1997-01-01), None
patent: WO 98/27970 (1998-07-01), None
patent: WO 92/14456 (2002-09-01), None
Cecil, Textbook of Medicine, 21st Edition, vol. 1, published 2000 by W.B. Saunders Company (PA), pp. 1061-1074.
Ansher, S.S. et al., “Biochemical Effects of Dithiolthiones”,Fd Chem Toxic, 1986, 24(5), 405-415.
Arbiser, J.L. et al., “The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice”,Journal of the American Academy of Dermatology, 1999, 40(6), Part 1, 925-929.
Arbiser, J.L. et al. “Oncogenic H-ras stimulates tumor angiogenesis by teo distinct pathways”,Proc. Natl. Acad. Sci. USA, 1997, 94, 861-866.
Bernatchez, P.N. et al., “Vascular Endothelial Growth Factor Effect on Endothelial Cell Proliferation, Migration, and Platelet-activating Factor Synthesis is Flk-1-dependent”,The Journal of Biological Chemistry, 1999, 274(43)31047-21054.
Bieder, A.et al., “Comparasion of the Metabolism of Oltipraz in the Mouse, Rat and Monkey and in Man”,Drug. Res., 1983, 33(11) No. 9, 1289-1297.
Bueding, E. et al., “The Antischistosomal Activity of Oltipraz”,Res. Comm. Chem. Path. Pharm. 1982, 37(2), 293-303.
Brown, K.J. et al., “A Novel In Vitro Assay for Human Angiogenesis”,Laboratory Investigation, 1996, 75(4), 539-555.
Clapper, M.L. et al., “Coordinate Induction of Glutathione S-Transferase β, μand π Expression in Murine Liver after a Single Administration of Olitipraz”,The American Society for Pharmacology and Experimental Therapeutics, 1994, 45, 469-474.
Clapper, M.L. “Comprehensive Activity of Oltipraz”,Pharmacol. Ther., 1998, 78(1), 17-27.
Deplanque, G. et al., “Anti-angiogenic agents: clinical trial design and therapies in development”,European Journal of Cancer, 2000, 36, 1713-1724.
Elmore, E. et al., “Correlation of Chemopreventive Efficacy Data from the Human Epidermal Cell Assay within vivoData”,Anticancer Research, 2000, 20, 27-32.
Folkman, J. MD., “Tumor Angiogenesis”,Cancer Medicine, 2000, 5thEdition, 132-152.
Fong, T.A.T. et al., “SU5416 Is a Potent and Selective Inhibitor of the Vascular Endothelial Growth Factor Receptor (Flk-1KDR) That Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types”,Cancer Research, 1999, 59, 99-106.
Gasparini, G. “The Rationale and Future Potential of Angiogenesis Inhibitors in Neoplasia”,Drugs, 1999, 58(1), 17-38.
Greene, T.W. et al.,Protective Groups in Organic Synthesis, 1991, 2ndEdition. Wiley & Sons.
Griffioen, A.W. et al., “Angiogenesis; Potentials for Pharmacologic Intervention in the Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation”,Pharmacol. Rev., 2000, 52(2), 237-268.
Hanahan, D. “Signaling Vascular Morphogenisis and Maintenance”,Science, 1997, 277, 48-50.
Heusse, D. et al., “Disposition of 14 C-Oltipraz in Animals”,Drug Res, 1985, 35(II), 9, 1431-1436.
Ilan, N. et al., “Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis”,Journal of Cell Science, 1998, 111, 3621-3631.
Ingeber, D. et al., “Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth”,Nature, 1990, 348, 555-557.
Jain, R.K. et al., “Quantitative angiogenesis assays: Progress and problems”,Nature Medicine, 1997, 3(11), 1203-1208.
Jones, M.K. et al., “Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing”,Nature Medicine, 1999, 5(12), 1418-1423.
Kensler, T.W. et al., “Olitpraz: Clinical Opportunities for Cancer Chemoprevention”,Journal of Cellular Biochemistry, 1995, 22, 101-107.
Kensler, T.W. et al., “Mechanism of Protection against Aflatoxin Tumorigenicity in Rats Fed 5-(2-Pyrazinyl)-4-methyl-1,2-dithiol-3-thione(Oltipraz) and Related 1,2-Dithiol-3-thiones and 1,2-Dithiol-3-ones”,Cancer Research, 1987, 47, 4271-4277.
Laird, A.D. et al., “SU6668 is a Potent Antiangiogenic and Antitumor Agent That Induces Regression of Established Tumors”,Cancer Research, 2000, 60, 4152-4160.
Liekens, S. et al., “A Novel Animal Model for Hemangiomas: Inhibition of Hemangioma Development by the Angiogenesis Inhibitor TNP-470”,Cancer Research, 1999, 59, 2376-2383.
Liu, Y.I. et al., “Protection by 5-(2-Pyrazinyl)-4-methyl-1, 2-dithiol-3-thione(Oltipraz) against the Hepatotoxicity of Alflatoxin B1 in the Rat”,Toxicology and Applied Pharmacology, 1988, 93, 442-451.
Malinda, K.M. et al., “Identification of laminin α1 and β1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting”,The FASAB Journal, 1999, 13, 53-62.
Masferrer, J.L. et al., “Antiangiogenic and ANtitumor Activities of Cyclooxygenase-2 Inhibitors”,Cancer Research, 2000, 60, 1306-1311.
Montesano, R. et al., “In vitro Rapid Organization of Endothelial Cells into Capillary-like Networks is Promoted by Collagen Matrices”,The Journal of Cell Biology, 1983, 97, 1648-1652.
Nicosia, R.F. et al., “Endogenous Regulation of Angiogenesis in the Rat Aorta Model”,American Journal of Pathology, 1997, 151(5), 1379-1386.
Nicosia, R.F. et al., “Autoregulation of Angiogenesis by Cells of the Vessel Wall”,International Review of Cytology, 1999, 185, 1-43.
O'Dwyer, P.J. et al., “The Chemopreventive Agent Oltipraz Stimulates Repair of Damaged DNA”,Cancer Research, 1997, 57, 1050-1053.
O'Dwyer, P.J. et al., “Cellular Kinetics of Induction by Oltipraz and Its Keto Derivative of Detoxication Enzymes in Human Colon Adenocarcinoma Cells”,Clin. Cancer Research, 1997, 3, 783-791.
Passaniti, A. et al., “Methods in Laboratory Investigation,” A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenice Agents Using Reconstituted Basement Membrane, Heparin, and fibroblast Growth Factor,Laboratory Investigation, 1992, 67(4), 519-528.
Plunkett, M.L. et al., “Methods in Laboratory Investigation, A In vivo Quantitative Angiogenesis Model Using Tumor Cells Entrapped in Alginate”,Laboratory Investigation, 1990, 62(4), 510-517.
Remington's Pharmaceutical Sciences(Mack Pub. Co., Easton Pa.), 1980.
Smith, W.A. et al., “Modulation of dibenzol[a}pyrene-DNA-adduction by chemopreventive agents in the human breast epithelial cell line MCF-7”,Proc. Am. Assoc. Cancer. Res., 1997, 38, 362.
Sun, L. et al.,“Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases”,J. Med. Chem., 1998, 2588-2603.
Wedge, S.R. et al.,“D4190: Am Orally Active Inhibitor of Vascular Endothelial Growth Factor Signaling with Broad-Spectrum Antitumor Efficacy”,Cancer Research, 2000, 60, 970-975.
Wood, J.M. et al., “PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Fcotr Receptor Tyrosine Kinases, Impairs V
Clapper Margie L.
Ruggeri Bruce A.
Dann Dorfman Herrell and Skillman, P.C.
Fox Chase Cancer Center
Hagan, Esq. Patrick J.
Henley III Raymond J.
LandOfFree
Methods for inhibiting angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3760088